AOMR · Angel Oak Mortgage REIT, Inc.

These shares of restricted stock vest in four equal annual installments, commencing on the one-year anniversary of the grant date, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.

Includes: 9,608 shares of unvested restricted stock which vests over four equal annual installments, with one remaining, which began on July 1, 2024, 9,120 shares of unvested restricted stock which vests over four equal annual installments, with two remaining, which began on July 1, 2025, and 19,380 shares of unvested restricted stock which vests over four equal annual installments, with three remaining, which began on July 1, 2026. All unvested restricted stock is subject to the reporting person's continued service to the Issuer throughout the applicable vesting dates.

The securities reported on this line are held directly by Xylem Finance LLC, a Delaware limited liability company ("Xylem"). Davidson Kempner Capital Management LP, a Delaware limited partnership and a registered investment adviser with the U.S. Securities and Exchange Commission ("DKCM") acts as investment manager to Xylem. DKCM GP LLC, a Delaware limited liability company, is the general partner of DKCM. The managing members of DKCM are Anthony A. Yoseloff, Conor Bastable, Morgan P. Blackwell, Patrick W. Dennis, Gabriel T. Schwartz, Zachary Z. Altschuler, Joshua D. Morris, Suzanne K. Gibbons, Gregory S. Feldman, Melanie Levine and James Li. Anthony A. Yoseloff through DKCM, is responsible for the voting and investment decisions relating to the securities held by Xylem reported herein.

The filing of this statement shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.

Includes the current grant of 11,737 shares of unvested restricted stock that vest on May 13, 2027 subject to the reporting person's continued service to the issuer through the applicable vesting date.

Includes the current grant of 11,737 shares of unvested restricted stock that vest on May 13, 2027 subject to the reporting person's continued service to the issuer through the applicable vesting date.

Includes the current grant of 11,737 shares of unvested restricted stock that vest on May 13, 2027 subject to the reporting person's continued service to the issuer through the applicable vesting date.

Includes the current grant of 11,737 shares of unvested restricted stock that vest on May 13, 2027 subject to the reporting person's continued service to the issuer through the applicable vesting date.

Includes the current grant of 11,737 shares of unvested restricted stock that vest on May 13, 2027 subject to the reporting person's continued service to the issuer through the applicable vesting date.

The securities reported on this line are held directly by Xylem Finance LLC, a Delaware limited liability company ("Xylem"). Davidson Kempner Capital Management LP, a Delaware limited partnership and a registered investment adviser with the U.S. Securities and Exchange Commission ("DKCM") acts as investment manager to Xylem. DKCM GP LLC, a Delaware limited liability company, is the general partner of DKCM. The managing members of DKCM are Anthony A. Yoseloff, Conor Bastable, Morgan P. Blackwell, Patrick W. Dennis, Gabriel T. Schwartz, Zachary Z. Altschuler, Joshua D. Morris, Suzanne K. Gibbons, Gregory S. Feldman, Melanie Levine and James Li. Anthony A. Yoseloff through DKCM, is responsible for the voting and investment decisions relating to the securities held by Xylem reported herein.

The filing of this statement shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.70 to $9.90, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

The securities reported on this line are held directly by Xylem Finance LLC, a Delaware limited liability company ("Xylem"). Davidson Kempner Capital Management LP, a Delaware limited partnership and a registered investment adviser with the U.S. Securities and Exchange Commission ("DKCM") acts as investment manager to Xylem. DKCM GP LLC, a Delaware limited liability company, is the general partner of DKCM. The managing members of DKCM are Anthony A. Yoseloff, Conor Bastable, Shulamit Leviant, Morgan P. Blackwell, Patrick W. Dennis, Gabriel T. Schwartz, Zachary Z. Altschuler, Joshua D. Morris, Suzanne K. Gibbons, Gregory S. Feldman, Melanie Levine and James Li. Anthony A. Yoseloff through DKCM, is responsible for the voting and investment decisions relating to the securities held by Xylem reported herein.

The filing of this statement shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.

Includes: 2,734 shares of unvested restricted stock which vests over four equal annual installments, with one remaining, which began on July 1, 2023, 9,608 shares of unvested restricted stock which vests over four equal annual installments, with two remaining, which began on July 1, 2024, 9,120 shares of unvested restricted stock which vests over four equal annual installments, with three remaining, which began on July 1, 2025, and 12,645 shares of unvested restricted stock which vests on July 1, 2026. All unvested restricted stock is subject to the reporting person's continued service to the Issuer throughout the applicable vesting dates.

These shares of restricted stock vest in four equal annual installments, commencing on the one-year anniversary of the grant date, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.

Includes: 2,734 shares of unvested restricted stock which vests over four equal annual installments, with one remaining, which began on July 1, 2023, 9,608 shares of unvested restricted stock which vests over four equal annual installments, with two remaining, which began on July 1, 2024, and 9,120 shares of unvested restricted stock which vests over four equal annual installments, with three remaining, which began on July 1, 2025. All unvested restricted stock is subject to the reporting person's continued service to the Issuer throughout the applicable vesting dates.

The securities reported on this line are held directly by Xylem Finance LLC, a Delaware limited liability company ("Xylem"). Davidson Kempner Capital Management LP, a Delaware limited partnership and a registered investment adviser with the U.S. Securities and Exchange Commission ("DKCM") acts as investment manager to Xylem. DKCM GP LLC, a Delaware limited liability company, is the general partner of DKCM. The managing members of DKCM are Anthony A. Yoseloff, Conor Bastable, Shulamit Leviant, Morgan P. Blackwell, Patrick W. Dennis, Gabriel T. Schwartz, Zachary Z. Altschuler, Joshua D. Morris, Suzanne K. Gibbons, Gregory S. Feldman, Melanie Levine and James Li. Anthony A. Yoseloff through DKCM, is responsible for the voting and investment decisions relating to the securities held by Xylem reported herein.

The filing of this statement shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.

Includes the current grant of 9,881 shares of unvested restricted stock that vest on May 14, 2026 subject to the reporting person's continued service to the issuer through the applicable vesting date.

Includes the current grant of 9,881 shares of unvested restricted stock that vest on May 14, 2026 subject to the reporting person's continued service to the issuer through the applicable vesting date.

Includes the current grant of 9,881 shares of unvested restricted stock that vest on May 14, 2026 subject to the reporting person's continued service to the issuer through the applicable vesting date.

Includes the current grant of 9,881 shares of unvested restricted stock that vest on May 14, 2026 subject to the reporting person's continued service to the issuer through the applicable vesting date.

Includes the current grant of 9,881 shares of unvested restricted stock that vest on May 14, 2026 subject to the reporting person's continued service to the issuer through the applicable vesting date.

The unit price shown is an average price.

Includes the current grant of 6,655 shares of unvested restricted stock that vest on May 15, 2025 subject to the reporting person's continued service to the issuer through the applicable vesting date.

Includes the current grant of 6,655 shares of unvested restricted stock that vest on May 15, 2025 subject to the reporting person's continued service to the issuer through the applicable vesting date.

The securities reported on this line are held directly by Xylem Finance LLC, a Delaware limited liability company ("Xylem"). Davidson Kempner Capital Management LP, a Delaware limited partnership and a registered investment adviser with the U.S. Securities and Exchange Commission ("DKCM") acts as investment manager to Xylem. DKCM GP LLC, a Delaware limited liability company, is the general partner of DKCM. The managing members of DKCM are Anthony A. Yoseloff, Conor Bastable, Shulamit Leviant, Morgan P. Blackwell, Patrick W. Dennis, Gabriel T. Schwartz, Zachary Z. Altschuler, Joshua D. Morris, Suzanne K. Gibbons and Zachary E. Gozali. Anthony A. Yoseloff through DKCM, is responsible for the voting and investment decisions relating to the securities held by Xylem reported herein.

The filing of this statement shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.13, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.16 to $11.17, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.45 to $11.46, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

Includes the current grant of 6,655 shares of unvested restricted stock that vest on May 15, 2025 subject to the reporting person's continued service to the issuer through the applicable vesting date.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.99 to $12.01, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

The securities reported on this line are held directly by Xylem Finance LLC, a Delaware limited liability company ("Xylem"). Davidson Kempner Capital Management LP, a Delaware limited partnership and a registered investment adviser with the U.S. Securities and Exchange Commission ("DKCM") acts as investment manager to Xylem. DKCM GP LLC, a Delaware limited liability company, is the general partner of DKCM. The managing members of DKCM are Anthony A. Yoseloff, Conor Bastable, Shulamit Leviant, Morgan P. Blackwell, Patrick W. Dennis, Gabriel T. Schwartz, Zachary Z. Altschuler, Joshua D. Morris, Suzanne K. Gibbons and Zachary E. Gozali. Anthony A. Yoseloff through DKCM, is responsible for the voting and investment decisions relating to the securities held by Xylem reported herein.

The filing of this statement shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.

These shares of restricted stock vest in four equal annual installments, commencing on the one-year anniversary of the grant date, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.

Includes: 5,469 shares of unvested restricted stock which vests over four equal annual installments, with two remaining, which began on July 1, 2023 and 14,411 shares of unvested restricted stock which vests over four equal annual installments, with three remaining, which began on July 1, 2024. All unvested restricted stock is subject to the reporting person's continued service to the Issuer throughout the applicable vesting dates.

Includes the current grant of 6,655 shares of unvested restricted stock that vest on May 15, 2025 subject to the reporting person's continued service to the issuer through the applicable vesting date.

Includes the current grant of 6,655 shares of unvested restricted stock that vest on May 15, 2025 subject to the reporting person's continued service to the issuer through the applicable vesting date.

Includes the current grant of 6,655 shares of unvested restricted stock that vest on May 15, 2025 subject to the reporting person's continued service to the issuer through the applicable vesting date.

Includes the current grant of 6,655 shares of unvested restricted stock that vest on May 15, 2025 subject to the reporting person's continued service to the issuer through the applicable vesting date.

Includes the current grant of 6,655 shares of unvested restricted stock that vest on May 15, 2025 subject to the reporting person's continued service to the issuer through the applicable vesting date.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.85 to $9.97, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

Includes the current grant of 9,708 shares of unvested restricted stock that vest on May 17, 2024 subject to the reporting person's continued service to the issuer through the applicable vesting date.

These shares of restricted stock vest in four equal annual installments, commencing on the one-year anniversary of the grant date, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.

Includes: 32,894 shares of unvested restricted stock which vest on June 21, 2024; 3,347 shares of unvested restricted stock which vests on March 11, 2024; and 8,203 shares of unvested restricted stock which vests over four equal annual installments, with three remaining, which began on July 1, 2023. All unvested restricted stock is subject to the reporting person's continued service to the Issuer throughout the applicable vesting dates.

Includes the current grant of 10,178 shares of unvested restricted stock that vest on May 17, 2024 subject to Mr. Jones' continued service to us through the applicable vesting date. Mr. Jones' vested stock is held solely in an individual brokerage account.

Includes the current grant of 10,178 shares of unvested restricted stock that vest on May 17, 2024 subject to Mr. Parsons' continued service to us through the applicable vesting date. The remainder of shares are held as tenant-in-common with Mr. Parson's spouse.

Includes the current grant of 10,178 shares of unvested restricted stock that vest on May 17, 2024 subject to Mr. Minami's continued service to us through the vesting date, along with 3,700 shares held in an individual retirement account and 14,726 held in an individual brokerage account.

Includes the current grant of 10,178 shares of unvested restricted stock that vest on May 17, 2024, subject to Ms. Jurinich?s continued service to us through the vesting date. Of the shares of our common stock included as beneficially owned by Ms. Jurinich, 12,857 shares are pledged to secure indebtedness owed by Ms. Jurinich in an individual brokerage account, and 1,920 shares are held in an individual retirement account.

Includes the current grant of 10,178 shares of unvested restricted stock that vest on May 17, 2024, subject to the reporting person's continued service to the Issuer through the applicable vesting date, 16,000 shares held in the reporting person's individual retirement account, and 10,226 shares held as tenant-in-common with the reporting person's spouse.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.19 to $6.25, inclusive. The reporting person undertakes to provide to Angel Oak Mortgage, Inc., any security holder of Angel Oak Mortgage, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) of this form.

Includes 6,015 shares of unvested restricted stock that vest on May 18, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting date; 16,000 shares held in the reporting person's individual retirement account (inclusive of the current purchase); and 4,211 shares held as tenant-in-common with the reporting person's spouse.